Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-510 in Healthy Subjects
NCT04731922Phase 1Completed
- Sponsor
- Takeda
- Start
- Feb 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAK-510 in nausea ((none)) and Vomiting (3 arms), sponsored by Takeda. Primary endpoints: Number of Participants Who Met the Markedly Abnormal Criteria for Vital Sign Measurements, Number of Participants Who Met the Markedly Abnormal Criteria for Electrocardiogram Parameters and 2 more. Started Feb 2021; status: completed.
02
Drugs
TAK-510
03
Conditions
nausea ((none))Vomiting
Beyond the preview
Go deeper on NCT04731922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04731922.